Overview

A Study to Investigate 14C-bemcentinib in Healthy Male Subjects

Status:
COMPLETED
Trial end date:
2022-09-23
Target enrollment:
Participant gender:
Summary
The aims of this Study were to determine: * How much of the Study Drug (bemcentinib) ends up in urine and faeces * How much of the Study Drug and its breakdown products get into the bloodstream * The breakdown products (metabolites) of the Study Drug * The safety of the Study Drug and any side effects that might be associated with it.
Phase:
PHASE1
Details
Lead Sponsor:
BerGenBio ASA
Treatments:
bemcentinib